mHealth app for caregiver instruction in manual therapy for chemotherapy-induced peripheral neuropathy

mHealth 应用程序用于指导护理人员进行化疗引起的周围神经病变的手法治疗

基本信息

  • 批准号:
    10482557
  • 负责人:
  • 金额:
    $ 39.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-18 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

Chemotherapy can damage nervous system structures leading to chemotherapy-induced peripheral neuropathy (CIPN) which impairs quality of life and daily functioning for millions of cancer survivors. Some 30% of recipients live with CIPN chronically beyond completion of chemotherapy. Conventional care is symptomatic including antidepressants, anticonvulsants, analgesics, vitamin supplements and topical gels to manage symptoms. While there are no FDA-approved treatments, evidence indicates that specific manual therapy techniques can reduce symptoms of CIPN. There is also evidence that caregivers can learn safe and effective manual therapy techniques for use in caregiving through multimedia instruction. However, there currently is no caregiver education product teaching specific techniques and safety precautions pertaining to CIPN. This project will develop a mobile health (mHealth) app to empower caregivers with knowledge, skills, self-efficacy and motivation to support loved ones with CIPN by use of simple manual techniques based on specific understanding and safety precautions for CIPN. The project will use a human-centered design approach in formative research to develop a “minimum viable product (MVP)” for the eventual caregiver mHealth app. A user-centered, iterative process with caregiver focus groups will guide development of the MVP which will then be assessed for feasibility through a Think-Aloud protocol. Specific Aims are as follows: Aim 1. Develop initial user-centered app design. We will develop preliminary requirements for core educational content to be featured in the app, then refine this with patient focus group feedback. The resulting initial app design will incorporate principles of ease of navigation, usability, utility, and engagement. Aim 2. Refine app design through an iterative process of qualitative feedback. The initial app design will be processed and revised through three rounds of caregiver focus groups for qualitative feedback and refinement. Qualitative analysis of responses after each round will be conducted, and applied to produce revised versions through round 3, resulting in the MVP prototype. Aim 3. Evaluate usability of a minimum viable product (MVP). Caregivers will experience the MVP prototype through an interactive Think-Aloud session with the design team that is recorded for qualitative analysis. This will be followed by debriefing with structured interview questions about design, relevance and intent to use. Quantitative data will assess system usability, and perceived relevance and impact on caregiving. Feasibility criteria will be usability scores and user ratings of perceived value and “intent to use” in caregiving. If Phase I is successful the app will be completed in Phase II followed by a large RCT to assess outcomes of use for both CIPN sufferers and caregivers. Eventual public health benefits include improved quality of life and functional well-being for the population of CIPN sufferers, reduced caregiver burden, and reduced economic burden from medical costs and lost productivity associated with CIPN.
化疗可损伤神经系统结构,导致化疗诱导的外周血淋巴细胞减少。 神经病变(CIPN)损害了数百万癌症幸存者的生活质量和日常功能。约30% 的接受者在完成化疗后长期患有CIPN。常规治疗是对症治疗 包括抗抑郁药、抗惊厥药、止痛药、维生素补充剂和局部凝胶, 症状虽然没有FDA批准的治疗方法,但有证据表明, 技术可以减少CIPN的症状。也有证据表明,照顾者可以学习安全有效 通过多媒体教学,使用手动治疗技术。然而,目前没有 护理人员教育产品,教导与CIPN有关的特定技术和安全预防措施。 该项目将开发一个移动的健康(mHealth)应用程序,使护理人员能够获得知识,技能, 自我效能和动机,以支持亲人与CIPN通过使用简单的手动技术的基础上, 对CIPN的具体理解和安全注意事项。该项目将采用以人为本的设计 形成性研究的方法,为最终的护理人员开发“最低可行产品(MVP)” 一个以用户为中心的,与护理人员焦点小组的迭代过程将指导 MVP,然后将通过一个大声思考方案评估其可行性。具体目标如下: 目标1。开发以用户为中心的应用程序设计。我们将制定核心的初步要求 应用程序中的教育内容,然后用患者焦点小组的反馈来完善这一点。所得 最初的应用程序设计将纳入易于导航、可用性、实用性和参与性的原则。 目标二。通过定性反馈的迭代过程优化应用程序设计。最初的APP 设计将通过三轮护理人员焦点小组进行处理和修订,以获得定性反馈 和精致。每轮调查结束后,将对答复进行定性分析,并用于产生 通过第三轮的修订版本,产生了MVP原型。 目标3。评估最小可行产品(MVP)的可用性。护理人员将体验MVP 通过与设计团队的互动式“大声思考”会议制作原型, 分析.随后将进行汇报,提出关于设计、相关性和 使用意图。定量数据将评估系统的可用性,以及感知的相关性和对系统的影响。 可行性标准将是可用性评分和用户对感知价值的评分以及在测试中的“使用意图”。 如果第一阶段成功,应用程序将在第二阶段完成,然后进行大型RCT评估 CIPN患者和护理人员的使用结果。最终的公共卫生效益包括改善 CIPN患者人群的生活质量和功能健康,减轻照顾者负担,以及 减少了医疗费用的经济负担和与CIPN相关的生产力损失。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM B COLLINGE其他文献

WILLIAM B COLLINGE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM B COLLINGE', 18)}}的其他基金

Palliative Care Provider Online Education in Evidence-Based Complementary Therapi
姑息治疗提供者循证补充治疗在线教育
  • 批准号:
    8124538
  • 财政年份:
    2011
  • 资助金额:
    $ 39.91万
  • 项目类别:
Mission Reconnect: Promoting Resilience and Re-Integration of Post-Deployment Vet
任务重新连接:促进部署后兽医的复原力和重新融入
  • 批准号:
    7909845
  • 财政年份:
    2010
  • 资助金额:
    $ 39.91万
  • 项目类别:
Mission Reconnect: Promoting Resilience and Reintegration of Post-Deployment Vete
任务重新连接:促进部署后退伍军人的复原力和重新融入
  • 批准号:
    8455262
  • 财政年份:
    2010
  • 资助金额:
    $ 39.91万
  • 项目类别:
Mission Reconnect: Promoting Resilience and Reintegration of Post-Deployment Vete
任务重新连接:促进部署后退伍军人的复原力和重新融入
  • 批准号:
    8550831
  • 财政年份:
    2010
  • 资助金额:
    $ 39.91万
  • 项目类别:
Web-based program for symptom management in fibromyalgia
基于网络的纤维肌痛症状管理程序
  • 批准号:
    7682195
  • 财政年份:
    2006
  • 资助金额:
    $ 39.91万
  • 项目类别:
Web-Based Program for Symptom Management in Fibromyalgia
基于网络的纤维肌痛症状管理程序
  • 批准号:
    7055466
  • 财政年份:
    2006
  • 资助金额:
    $ 39.91万
  • 项目类别:
Web-based program for symptom management in fibromyalgia
基于网络的纤维肌痛症状管理程序
  • 批准号:
    7539640
  • 财政年份:
    2006
  • 资助金额:
    $ 39.91万
  • 项目类别:
Promoting Healthy Aging through "Elder-Healer" Training
通过“老年治疗师”培训促进健康老龄化
  • 批准号:
    6790363
  • 财政年份:
    2004
  • 资助金额:
    $ 39.91万
  • 项目类别:
Couples and Cancer: Building Partner Efficacy in Caring
夫妻与癌症:建立伴侣的护理效能
  • 批准号:
    6694548
  • 财政年份:
    2003
  • 资助金额:
    $ 39.91万
  • 项目类别:
Couples and Cancer: Building Partner Efficacy in Caring
夫妻与癌症:建立伴侣的护理效能
  • 批准号:
    7219065
  • 财政年份:
    2003
  • 资助金额:
    $ 39.91万
  • 项目类别:

相似海外基金

Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
  • 批准号:
    10641500
  • 财政年份:
    2023
  • 资助金额:
    $ 39.91万
  • 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
  • 批准号:
    10485593
  • 财政年份:
    2023
  • 资助金额:
    $ 39.91万
  • 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
  • 批准号:
    10728526
  • 财政年份:
    2023
  • 资助金额:
    $ 39.91万
  • 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
  • 批准号:
    10638278
  • 财政年份:
    2023
  • 资助金额:
    $ 39.91万
  • 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
  • 批准号:
    10621646
  • 财政年份:
    2023
  • 资助金额:
    $ 39.91万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10425794
  • 财政年份:
    2022
  • 资助金额:
    $ 39.91万
  • 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
  • 批准号:
    22K19602
  • 财政年份:
    2022
  • 资助金额:
    $ 39.91万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
  • 批准号:
    10512672
  • 财政年份:
    2022
  • 资助金额:
    $ 39.91万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10721752
  • 财政年份:
    2022
  • 资助金额:
    $ 39.91万
  • 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
  • 批准号:
    10821681
  • 财政年份:
    2022
  • 资助金额:
    $ 39.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了